Jul 25 |
Super League Enterprise And 2 Other Stocks Under $2 Insiders Are Buying
|
Jul 22 |
aTyr Pharma Completes Enrollment in Global Pivotal Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis
|
Jul 12 |
aTyr Pharma, Inc. (NASDAQ:ATYR) is largely controlled by institutional shareholders who own 61% of the company
|
Jun 5 |
Millionaire Makers: 7 Stocks You Can Buy for $2 That Can 10X by 2025
|
Jun 5 |
Timothy Coughlin Bought 833% More Shares In aTyr Pharma
|
Jun 3 |
aTyr Pharma announces Nasdaq ticker symbol change to “ATYR”
|
Jun 3 |
aTyr Pharma Announces Nasdaq Stock Ticker Symbol Change from “LIFE” to “ATYR”
|
May 24 |
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
May 15 |
aTyr Pharma to Present Poster Describing Efzofitimod’s Mechanism of Action at the American Thoracic Society 2024 International Conference
|
May 14 |
aTyr Pharma Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis
|